Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques

Jingyou Yu; Paul V. Thomas; Michaela Sciacca; Cindy Wu; Jinyan Liu; Xuan He; Jessica Miller; Nicole P. Hachmann; Nehalee Surve; Katherine McMahan; Catherine Jacob-Dolan; Olivia Powers; Kevin Hall; Julia Barrett; David Hope; Camille R. Mazurek; Tetyana Murdza; William C. Chang; Emily Golub; Phyllis A. Rees; Caroline E. Peterson; Agnes Hajduczki; Wei Hung Chen; Elizabeth J. Martinez; Elizabeth Hussin; Camille Lange; Hua Gong; Gary R. Matyas; Mangala Rao; Mehul Suthar; Mona Boursiquot; Anthony Cook; Laurent Pessaint; Mark G. Lewis; Hanne Andersen; Diane L. Bolton; Nelson L. Michael; M. Gordon Joyce; Kayvon Modjarrad; Dan H. Barouch

doi:10.1016/j.xcrm.2023.101018

Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques

Jingyou Yu, Paul V. Thomas, Michaela Sciacca, Cindy Wu, Jinyan Liu, Xuan He, Jessica Miller, Nicole P. Hachmann, Nehalee Surve, Katherine McMahan, Catherine Jacob-Dolan, Olivia Powers, Kevin Hall, Julia Barrett, David Hope, Camille R. Mazurek, Tetyana Murdza, William C. Chang, Emily Golub, Phyllis A. ReesCaroline E. Peterson, Agnes Hajduczki, Wei Hung Chen, Elizabeth J. Martinez, Elizabeth Hussin, Camille Lange, Hua Gong, Gary R. Matyas, Mangala Rao, Mehul Suthar, Mona Boursiquot, Anthony Cook, Laurent Pessaint, Mark G. Lewis, Hanne Andersen, Diane L. Bolton, Nelson L. Michael, M. Gordon Joyce^*, Kayvon Modjarrad, Dan H. Barouch^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines demonstrate reduced protection against acquisition of BA.5 subvariant but are still effective against severe disease. However, immune correlates of protection against BA.5 remain unknown. We report the immunogenicity and protective efficacy of vaccine regimens consisting of the vector-based Ad26.COV2.S vaccine and the adjuvanted spike ferritin nanoparticle (SpFN) vaccine against a high-dose, mismatched Omicron BA.5 challenge in macaques. The SpFNx3 and Ad26 + SpFNx2 regimens elicit higher antibody responses than Ad26x3, whereas the Ad26 + SpFNx2 and Ad26x3 regimens induce higher CD8 T cell responses than SpFNx3. The Ad26 + SpFNx2 regimen elicits the highest CD4 T cell responses. All three regimens suppress peak and day 4 viral loads in the respiratory tract, which correlate with both humoral and cellular immune responses. This study demonstrates that both homologous and heterologous regimens involving Ad26.COV2.S and SpFN vaccines provide robust protection against a mismatched BA.5 challenge in macaques.

Original language	English
Article number	101018
Journal	Cell Reports Medicine
Volume	4
Issue number	4
DOIs	https://doi.org/10.1016/j.xcrm.2023.101018
State	Published - 18 Apr 2023
Externally published	Yes

Keywords

B cell
BA.5
Omicron
SARS-CoV-2
T cell
antibody
macaque
vaccine

Access to Document

10.1016/j.xcrm.2023.101018

Cite this

Yu, J., Thomas, P. V., Sciacca, M., Wu, C., Liu, J., He, X., Miller, J., Hachmann, N. P., Surve, N., McMahan, K., Jacob-Dolan, C., Powers, O., Hall, K., Barrett, J., Hope, D., Mazurek, C. R., Murdza, T., Chang, W. C., Golub, E., ... Barouch, D. H. (2023). Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques. Cell Reports Medicine, 4(4), Article 101018. https://doi.org/10.1016/j.xcrm.2023.101018

@article{fc62a97abaf64382bc1b3e083e703917,

title = "Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques",

abstract = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines demonstrate reduced protection against acquisition of BA.5 subvariant but are still effective against severe disease. However, immune correlates of protection against BA.5 remain unknown. We report the immunogenicity and protective efficacy of vaccine regimens consisting of the vector-based Ad26.COV2.S vaccine and the adjuvanted spike ferritin nanoparticle (SpFN) vaccine against a high-dose, mismatched Omicron BA.5 challenge in macaques. The SpFNx3 and Ad26 + SpFNx2 regimens elicit higher antibody responses than Ad26x3, whereas the Ad26 + SpFNx2 and Ad26x3 regimens induce higher CD8 T cell responses than SpFNx3. The Ad26 + SpFNx2 regimen elicits the highest CD4 T cell responses. All three regimens suppress peak and day 4 viral loads in the respiratory tract, which correlate with both humoral and cellular immune responses. This study demonstrates that both homologous and heterologous regimens involving Ad26.COV2.S and SpFN vaccines provide robust protection against a mismatched BA.5 challenge in macaques.",

keywords = "B cell, BA.5, Omicron, SARS-CoV-2, T cell, antibody, macaque, vaccine",

author = "Jingyou Yu and Thomas, {Paul V.} and Michaela Sciacca and Cindy Wu and Jinyan Liu and Xuan He and Jessica Miller and Hachmann, {Nicole P.} and Nehalee Surve and Katherine McMahan and Catherine Jacob-Dolan and Olivia Powers and Kevin Hall and Julia Barrett and David Hope and Mazurek, {Camille R.} and Tetyana Murdza and Chang, {William C.} and Emily Golub and Rees, {Phyllis A.} and Peterson, {Caroline E.} and Agnes Hajduczki and Chen, {Wei Hung} and Martinez, {Elizabeth J.} and Elizabeth Hussin and Camille Lange and Hua Gong and Matyas, {Gary R.} and Mangala Rao and Mehul Suthar and Mona Boursiquot and Anthony Cook and Laurent Pessaint and Lewis, {Mark G.} and Hanne Andersen and Bolton, {Diane L.} and Michael, {Nelson L.} and Joyce, {M. Gordon} and Kayvon Modjarrad and Barouch, {Dan H.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = apr,

day = "18",

doi = "10.1016/j.xcrm.2023.101018",

language = "English",

volume = "4",

journal = "Cell Reports Medicine",

issn = "2666-3791",

number = "4",

}

Yu, J, Thomas, PV, Sciacca, M, Wu, C, Liu, J, He, X, Miller, J, Hachmann, NP, Surve, N, McMahan, K, Jacob-Dolan, C, Powers, O, Hall, K, Barrett, J, Hope, D, Mazurek, CR, Murdza, T, Chang, WC, Golub, E, Rees, PA, Peterson, CE, Hajduczki, A, Chen, WH, Martinez, EJ, Hussin, E, Lange, C, Gong, H, Matyas, GR, Rao, M, Suthar, M, Boursiquot, M, Cook, A, Pessaint, L, Lewis, MG, Andersen, H, Bolton, DL, Michael, NL, Joyce, MG, Modjarrad, K & Barouch, DH 2023, 'Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques', Cell Reports Medicine, vol. 4, no. 4, 101018. https://doi.org/10.1016/j.xcrm.2023.101018

TY - JOUR

T1 - Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques

AU - Yu, Jingyou

AU - Thomas, Paul V.

AU - Sciacca, Michaela

AU - Wu, Cindy

AU - Liu, Jinyan

AU - He, Xuan

AU - Miller, Jessica

AU - Hachmann, Nicole P.

AU - Surve, Nehalee

AU - McMahan, Katherine

AU - Jacob-Dolan, Catherine

AU - Powers, Olivia

AU - Hall, Kevin

AU - Barrett, Julia

AU - Hope, David

AU - Mazurek, Camille R.

AU - Murdza, Tetyana

AU - Chang, William C.

AU - Golub, Emily

AU - Rees, Phyllis A.

AU - Peterson, Caroline E.

AU - Hajduczki, Agnes

AU - Chen, Wei Hung

AU - Martinez, Elizabeth J.

AU - Hussin, Elizabeth

AU - Lange, Camille

AU - Gong, Hua

AU - Matyas, Gary R.

AU - Rao, Mangala

AU - Suthar, Mehul

AU - Boursiquot, Mona

AU - Cook, Anthony

AU - Pessaint, Laurent

AU - Lewis, Mark G.

AU - Andersen, Hanne

AU - Bolton, Diane L.

AU - Michael, Nelson L.

AU - Joyce, M. Gordon

AU - Modjarrad, Kayvon

AU - Barouch, Dan H.

PY - 2023/4/18

Y1 - 2023/4/18

N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines demonstrate reduced protection against acquisition of BA.5 subvariant but are still effective against severe disease. However, immune correlates of protection against BA.5 remain unknown. We report the immunogenicity and protective efficacy of vaccine regimens consisting of the vector-based Ad26.COV2.S vaccine and the adjuvanted spike ferritin nanoparticle (SpFN) vaccine against a high-dose, mismatched Omicron BA.5 challenge in macaques. The SpFNx3 and Ad26 + SpFNx2 regimens elicit higher antibody responses than Ad26x3, whereas the Ad26 + SpFNx2 and Ad26x3 regimens induce higher CD8 T cell responses than SpFNx3. The Ad26 + SpFNx2 regimen elicits the highest CD4 T cell responses. All three regimens suppress peak and day 4 viral loads in the respiratory tract, which correlate with both humoral and cellular immune responses. This study demonstrates that both homologous and heterologous regimens involving Ad26.COV2.S and SpFN vaccines provide robust protection against a mismatched BA.5 challenge in macaques.

AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines demonstrate reduced protection against acquisition of BA.5 subvariant but are still effective against severe disease. However, immune correlates of protection against BA.5 remain unknown. We report the immunogenicity and protective efficacy of vaccine regimens consisting of the vector-based Ad26.COV2.S vaccine and the adjuvanted spike ferritin nanoparticle (SpFN) vaccine against a high-dose, mismatched Omicron BA.5 challenge in macaques. The SpFNx3 and Ad26 + SpFNx2 regimens elicit higher antibody responses than Ad26x3, whereas the Ad26 + SpFNx2 and Ad26x3 regimens induce higher CD8 T cell responses than SpFNx3. The Ad26 + SpFNx2 regimen elicits the highest CD4 T cell responses. All three regimens suppress peak and day 4 viral loads in the respiratory tract, which correlate with both humoral and cellular immune responses. This study demonstrates that both homologous and heterologous regimens involving Ad26.COV2.S and SpFN vaccines provide robust protection against a mismatched BA.5 challenge in macaques.

KW - B cell

KW - BA.5

KW - Omicron

KW - SARS-CoV-2

KW - T cell

KW - antibody

KW - macaque

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85151691872&partnerID=8YFLogxK

U2 - 10.1016/j.xcrm.2023.101018

DO - 10.1016/j.xcrm.2023.101018

M3 - Article

C2 - 37023746

AN - SCOPUS:85151691872

SN - 2666-3791

VL - 4

JO - Cell Reports Medicine

JF - Cell Reports Medicine

IS - 4

M1 - 101018

ER -

Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques

Abstract

Keywords

Access to Document

Fingerprint

Cite this